Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785688 | 0.85 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1MAPTTDP1RAB9A | |
| SCHEMBL18704479 | 0.85 | MRGPRX4 (0.46) | MRGPRX4ALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL3719155 | 0.82 | HPGD (0.40) | ALDH1A1L3MBTL1MAPTHPGDTDP1 | |
| SCHEMBL23074907 | 0.81 | MRGPRX4 (0.46) | MRGPRX4ALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL6047049 | 0.79 | HPGD (0.50) | ALDH1A1L3MBTL1MAPTHPGDTDP1 | |
| SCHEMBL1547751 | 0.79 | L3MBTL1 (0.54) | MRGPRX4ALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL74492 | 0.79 | HTR7 (0.57) | ALDH1A1L3MBTL1MAPTHPGDTDP1 | |
| SCHEMBL31259416 | 0.79 | HTR7 (0.57) | ALDH1A1L3MBTL1MAPTHPGDTDP1 | |
| SCHEMBL30272016 | 0.78 | MRGPRX4 (0.47) | MRGPRX4ALDH1A1L3MBTL1MAPTHPGD | |
| SCHEMBL28912859 | 0.78 | MRGPRX4 (0.47) | MRGPRX4ALDH1A1L3MBTL1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482579-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LHOTSE BIO, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4482579-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-119110795-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240376054-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-11884627-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LHOTSE BIO, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023160672-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO , INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR2, LPAR1, LPAR6 | MRGPRX4 134/4885ALDH1A1 1863/4885L3MBTL1 3055/4885 |
| US-11884627-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LPAR2, LPAR1, LPAR6 | MRGPRX4 134/4885ALDH1A1 1863/4885L3MBTL1 3055/4885 |
| US-20240376054-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR2, LPAR1, LPAR6 | MRGPRX4 134/4885ALDH1A1 1863/4885L3MBTL1 3055/4885 |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LPAR2, LPAR1, LPAR6 | MRGPRX4 134/4885ALDH1A1 1863/4885L3MBTL1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.